Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Inovio, MVI collaborate to advance malaria vaccine development and new delivery technologies

The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. today announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies.

7 Jan 2013

Report shows how P. gingivalis manipulates body's immune system to disable normal processes

A new research report published in the Journal of Leukocyte Biology shows how the bacteria known for causing gum disease--Porphyromonas gingivalis--manipulates the body's immune system to disable normal processes that would otherwise destroy it. Specifically, the report shows that this pathogen prompts the production of the anti-inflammatory molecule Interleukin-10 (IL-10).

4 Jan 2013

Pfizer, Repligen sign licensing deal to advance spinal muscular atrophy program

Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

3 Jan 2013

Adrenomed creates Adrecizumab to decrease death rates from sepsis

The German corporation Adrenomed AG today announced its intentions to contribute to the reduction of mortality from sepsis and septic shock. Sepsis is an advanced systemic infection that travels via the blood stream to many of the body's vital organs, which can lead to death and disability.

3 Jan 2013

Uncharacterized TLR plays key role in Toxoplasma gondii response

A previously uncharacterized toll-like receptor appears to play a crucial role in the innate immune response to Toxoplasma gondii infection and may promote host resistance, potentially leading to anti-parasite vaccines, say US researchers.

28 Dec 2012

Antibody type prognostic for myasthenia gravis patients

Patients who have myasthenia gravis are more likely to have a severe form of the disease and more difficulty achieving remission if they are seropositive for antibodies to muscle-specific kinase, report researchers.

24 Dec 2012

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with hematologic cancers.

21 Dec 2012

Acorda Therapeutics acquires Neuronex

Acorda Therapeutics, Inc. today announced that the Company has completed the acquisition of Neuronex, Inc., a privately held company developing a nasal spray formulation of diazepam. Under the terms of the agreement, Acorda paid $6.8 million to Neuronex to complete the acquisition.

21 Dec 2012

US FDA approves raxibacumab for treating inhalational anthrax

The US Food and Drug Administration have approved the monoclonal antibody raxibacumab for treatment of inhalational anthrax, caused by breathing in spores of Bacillus anthracis.

19 Dec 2012

Allakos closes $32M Series A financing to develop antibody-based therapeutics

Allakos Inc. announced today that it has completed a $32 million Series A preferred stock financing led by Novo Ventures with participation from Alta Partners, RiverVest Venture Partners and the Roche Venture Fund. Peter Moldt , PhD., Partner at Novo Ventures, Robert Alexander , PhD., Director at Alta Partners and John McKearn PhD., Managing Director at RiverVest Venture Partners, will join the Board of Directors.

17 Dec 2012

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

The U.S. Food and Drug Administration today approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

14 Dec 2012

Scientists discover FAIM molecule as potential biomarker for bone marrow cancer

Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow.

14 Dec 2012

NovaDigm announces data from NDV-3 vaccine Phase 1 study on Candida and Staph infections

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the publication of data from its first-in-human Phase 1 study of its NDV-3 vaccine program in the journal Vaccine.

13 Dec 2012

Scientists isolate cancer stem cells that lead to growth of Wilms' tumours

Scientists have isolated cancer stem cells that lead to the growth of Wilms' tumours, a type of cancer typically found in the kidneys of young children. The researchers have used these cancer stem cells to test a new therapeutic approach that one day might be used to treat some of the more aggressive types of this disease.

13 Dec 2012

Doctors should use different therapies when treating older and younger patients with CLL

Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

13 Dec 2012

Eli Lilly provides update on solanezumab Phase 3 clinical study for mild Alzheimer's

Eli Lilly and Company today provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer's disease.

13 Dec 2012

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition.

12 Dec 2012

U-M devises new system to capture and study circulating tumor cells

A glass plate with a nanoscale roughness could be a simple way for scientists to capture and study the circulating tumor cells that carry cancer around the body through the bloodstream.

12 Dec 2012

Study finds important links between Pf malaria and endemic Burkitt Lymphoma

New research, presented this morning at the 54th Annual Meeting of the American Society of Hematology (ASH), has identified important associations between Plasmodium falciparum (Pf) malaria and endemic Burkitt Lymphoma (eBL) that may help researchers identify young children who are more susceptible to eBL.

12 Dec 2012